About Us

Joel is a partner at Innovation Endeavors and an experienced leader, medical professional, researcher, and entrepreneur. Joel previously served as the Chief Scientific Officer at Tempus, a company focused on bringing the power of data and artificial intelligence to healthcare. Before joining Tempus, Joel was an Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the Mount Sinai Health System. Prior to joining Innovation Endeavors, Joel co-founded Onegevity Health (acquired by Thorne), a company developing health intelligence platforms for preventative health, and NuMedii, a company developing machine learning and A.I. approaches for drug discovery. Joel earned a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from the Stanford University School of Medicine.

Nick Saccomano joins the BioLoomics board of directors with over 35 years of research, development, and management experience across a multitude of therapeutic areas. Nick most recently served as Chief Science Officer and site head at Pfizer Boulder R & D, formally Array BioPharma Inc., where he grew and advanced a portfolio of small molecule oncology programs from inception to proof-of-concept. Over his varied career, Dr. Saccomano has guided the discovery and development of dozens of molecules resulting in several commercial introductions. Nick’s appointment will complement the strengths of the BioLoomics leadership and advisory groups, while contributing deep insights into platform development, strategic direction and portfolio/clinical applications.

Starting with $10K in personal funds, Natanel Barookhian has guided, pruned, and grown TechU into one of the most selective and best-performing seed funds on the East Coast. Born into a single-parent home of modest means, Natanel’s worldview was shaped by early immigration to the United States. Armed with four languages and an MBA from MIT, he engages tenacious entrepreneurs from around the world in search of next-generation deep tech with lasting implications.

Michael Stowell is CSO of AmideBio and an Associate Professor of Molecular Biology and Mechanical Engineering at the University of Colorado, Boulder. He has authored numerous publications in the fields of synthetic organic chemistry, structural biology, neurobiology, and biophysics. Michael has received multiple grants and awards including the Beckman Young Investigator Award, a National Institutes of Health EUREKA award and a Howard Hughes Medical Institute Collaborative Innovation Award. Michael received his Ph.D. in Chemistry and Biophysics from the California Institute of Technology and was a visiting Scientist at the MRC – Laboratory of Molecular Biology, Cambridge England and the Biophysics Department of Kyoto University, Japan.

Viswa is the founder and CEO of Enveda Biosciences. He has led the company through successful fundraising rounds and the scale-up of its discovery platform, which is based on metabolomics and machine learning, to unearth new medicines from its first-of-a-kind chemical map of the natural world. Before founding Enveda, Viswa led multiple drug development efforts at Recursion Pharmaceuticals. He earned his Ph.D. in immuno-oncology at the University of Wisconsin-Madison, where he developed candidate therapeutics for prostate cancer. Outside of work, Viswa loves playing racquet sports of all kinds and trying to read about a dozen books in parallel.

Aaron is CSO of Twist Bioscience and is a proven biologics leader adept at managing teams to discover novel first-in-class antibody therapeutics. Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.

George leads Synthetic Biology at the Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT).